When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

Therefore, it remains to be seen whether the desired price reduction can be achieved or not." Currently, two innovators are ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of seemingly reputable online pharmacies in search of weight loss drugs at a discounted price. The temptation is ...

We got some good news from the poor old entertainment companies this earnings season. Video streaming is finally becoming a ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

The vast majority of Wegovy sales (more than DKK 31 billion) were recorded in the US, where Novo Nordisk said increased volumes and formulary access had combined to offset lower prices.

Hims & Hers Health launched a GLP-1 Supply Tracker to spotlight challenges in accessing obesity medications, addressing ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...